About Company:
Kimia Kala Razi Pharmaceutical Co. (Public Joint Stock)
Established in 2012, Kimia Kala Razi Pharmaceutical Co. (Public Joint Stock) was founded with the objective of producing high-quality, innovative healthcare solutions. The company’s journey began in 2015 with the launch of its flagship product, Argosol, targeting ophthalmic conditions. Kimia Kala Razi is a recognized knowledge-based enterprise, holding Nano-scale approval from the Nano Technology Development Headquarters of the Vice Presidency for Science and Technology. Today, the company offers a robust portfolio of over 40 pharmaceutical, supplement, and health products, addressing a wide spectrum of medical needs across society.
In 2025, following a strategic restructuring from a Private Joint Stock to a Public Joint Stock company, Kimia Kala Razi initiated a public offering on the Iran Fara Bourse. Our production facility, spanning 3,000 square meters, is strategically located in the Mamounieh Industrial Zone, 70 kilometers from Tehran. This site houses 10 distinct production lines capable of manufacturing a diverse range of dosage forms, including tablets, sachets, effervescent tablets, capsules, drops, syrups, and topical treatments such as solutions, creams, and therapeutic shampoos. It is noteworthy that our facility holds GMP certification from the Food and Drug Administration (FDA), and our laboratories are accredited by the Reference Laboratory of the Ministry of Health.
To meet both domestic and international market demands, and in line with our growth trajectory, construction of our second production facility is underway. Dedicated to the production of injectable drugs, this plant is scheduled to be operational by 2027.
Kimia Kala Razi is committed to leveraging expert human capital, scientific management, and cutting-edge pharmaceutical knowledge to deliver consistent quality and high productivity. We strive to secure a distinguished position in safeguarding the health of the community while creating sustainable value for all our stakeholders.
